Covaxin has already been granted Emergency Use Listing (EUL) in 13 countries as on January 31 according to the WHO. Covaxin was granted EUL...

Ahmedabad-based Hester Biosciences is a part of Gujarat Covid Vaccine Consortium (GCVC), which in May this year signed an agreement with Bh...

Covaxin was also reviewed by WHO's Strategic Advisory Group of Experts on Immunisation (SAGE), which recommended the use of the vaccine in ...

WHO's TAG is an independent advisory group that provides recommendations to the WHO on whether a Covid 19 vaccine can be listed for emergen...

Hyderabad-based Bharat Biotech, which has developed Covaxin, submitted EOI (Expression of Interest) to the WHO on April 19 for the vaccine'...

Bharat Biotech's Covaxin and AstraZeneca and Oxford University's Covishield are the two widely used vaccines in India.

While the WHO has so far approved Covid-19 vaccines of Pfizer-BioNTech, AstraZeneca-SK Bio/Serum Institute of India, Johnson & Johnson-Jans...

While the WHO has so far approved Covid-19 vaccines of Pfizer-BioNTech, AstraZeneca-SK Bio/Serum Institute of India, Johnson & Johnson-Jans...

WHO had earlier said that Bharat Biotech has been submitting data to it on a rolling basis and had submitted additional information on 27 S...

"The trials are ongoing, and we expect to submit data by the end of this year," a company insider said. The trials, including over 600 part...

"This represents one of the first approvals worldwide for COVID-19 vaccines for the 2-18 age group. Bharat Biotech sincerely thanks the DCG...

Bharat Biotech's pre-submission meeting has been scheduled on June 23 for evaluation of the World Health Organisation (WHO)'s Emergency Use...

"The National Regulator of the country, the Drugs Controller General of India (DCGI), after careful examination, has accepted the recommend...

Bharat Biotech has written to the department of biotechnology for funds to expand its manufacturing capacities. “The company has asked for ...

The company has written to the Department of Biotechnology seeking Rs 100 crore to ramp up its manufacturing capacity.

The trials involved 25,800 participants and was conducted in partnership with the Indian government's medical research body.

"This is India's first phase-III efficacy study for a Covid-19 vaccine, and the largest phase-III efficacy trial ever conducted in India," ...